Rate of Requests to Return to Intravenous Biologic Disease-Modifying Antirheumatic Drug Therapy After an Intravenous-to-Subcutaneous Switch in Rheumatoid Arthritis

During the coronavirus disease 2019 (COVID-19) pandemic, many patients with rheumatoid arthritis (RA) were switched from intravenous (IV) to subcutaneous (SC) biologic therapies to reduce hospital visits. Although comparable efficacy between the 2 routes has been reported for abatacept and tocilizumab,1-4 real-world data on patient experience following an externally imposed treatment transition remain limited.

Authors

Institutions

Publication Details

Journal
The Journal of Rheumatology
Published
2026-11-15
DOI
https://doi.org/10.3899/jrheum.2026-0406
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rate of Requests to Return to Intravenous Biologic Disease-Modifying Antirheumatic Drug Therapy After an Intravenous-to-Subcutaneous Switch in Rheumatoid Arthritis

S. Trijau, Nathalie Balandraud, Pierre Lafforgue, Théo Wirth et al.
The Journal of Rheumatology
Rheumatoid Arthritis Research and Therapies
article

Rate of Requests to Return to Intravenous Biologic Disease-Modifying Antirheumatic Drug Therapy After an Intravenous-to-Subcutaneous Switch in Rheumatoid Arthritis

S. Trijau, Nathalie Balandraud, Pierre Lafforgue, Théo Wirth, E. Fockens, Thao Pham, Lisa Diebold
article en

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, many patients with rheumatoid arthritis (RA) were switched from intravenous (IV) to subcutaneous (SC) biologic therapies to reduce hospital visits. Although comparable efficacy between the 2 routes has been reported for abatacept and tocilizumab,1-4 real-world data on patient experience following an externally imposed treatment transition remain limited.

The Journal of Rheumatology
Centre National de la Recherche Scientifique (FR), Inserm (FR), Aix-Marseille Université (FR), Assistance Publique Hôpitaux de Marseille (FR), Hôpital Sainte-Marguerite (FR), Centre de Recherche en Cancérologie de Marseille (FR), ARTHritEs, Microchimérisme et InflammationS (FR)
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Rate of Requests to Return to Intravenous Biologic Disease-Modifying Antirheumatic Drug Therapy After an Intravenous-to-Subcutaneous Switch in Rheumatoid Arthritis — S. Trijau, Nathalie Balandraud, et al. · The Journal of Rheumatology (2026) | TGRS Research Map | TGRS